Open Access<p>Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report</p>
Author(s) -
Zhao-Bo Liu,
Fachao Zhi,
Guangming Li,
Dongdong Lin
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s261521
Subject(s) - medicine , lenvatinib , hepatocellular carcinoma , liver function , stage (stratigraphy) , progressive disease , milan criteria , liver cancer , liver transplantation , surgery , gastroenterology , oncology , sorafenib , disease , transplantation , paleontology , biology
The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that excludes them from potentially curative surgical treatment. Lenvatinib is associated with a high objective response rate (ORR) (40.6%) in advanced HCC, indicating the potential for tumor downstaging and conversion to surgical intervention. We report the case of a patient with recurrent, advanced HCC who achieved a partial response and downstaging following third-line treatment with lenvatinib but missed the opportunity for conversion hepatectomy.